“The present scenario has uncovered some structural weaknesses from the EU’s medicines supply chain as well as a higher dependence on non-EU nations around the world for active pharmaceutical ingredients,” Kyriakides mentioned. She recommended that supply chain issues be resolved within an EU pharmaceutical method predicted to be launched by